SAINT-HERBLAIN, FRANCE — November 26, 2025. Valneva has announced positive final Phase 2 results for its Lyme disease vaccine candidate VLA15, showing strong antibody persistence and a favorable safety profile six months after a third yearly booster dose, according to data from the VLA15-221 trial. These results reinforce the candidate’s potential as the first human Lyme disease vaccine in decades, with all vaccinations already completed in the pivotal VALOR Phase 3 trial conducted with Pfizer. The findings confirm the need for yearly vaccination prior to each Lyme season, supporting VLA15’s progression toward regulatory submissions in 2026.
Science Significance
VLA15’s Phase 2 data show a robust anamnestic immune response across all six OspA serotypes, with antibody levels remaining well above baseline at month 48—six months after the latest booster dose. This sustained response was observed across all age groups, including adults, adolescents, and the 5–11 pediatric cohort, who demonstrated the highest geometric mean fold rises, reaching 15.5–28.5-fold increases depending on serotype. As detailed on page 1 of the file, the study compared two dosing schedules and confirmed that a three-dose primary regimen yielded stronger immunogenicity than a two-dose schedule. VLA15’s design, which targets the outer surface protein A (OspA) of Borrelia burgdorferi, blocks transmission of Lyme-causing bacteria from tick to human and covers the six most prevalent serotypes across North America and Europe. These findings validate VLA15’s scientific foundation and support its biologic rationale as a next-generation preventive vaccine.
Regulatory Significance
The strong Phase 2 performance strengthens VLA15’s regulatory trajectory ahead of expected submissions to the FDA (BLA) and EMA (MAA) in 2026, contingent on successful Phase 3 outcomes. According to page 1, an independent Data Monitoring Committee (DMC) reported no safety concerns across any age group, a critical requirement for regulatory confidence, especially in vaccines intended for widespread seasonal use. The study’s randomized, observer-blind, placebo-controlled design—outlined on page 2—adds robustness to the clinical dataset, particularly as VLA15 is the only Lyme vaccine candidate in advanced clinical development. Its annual booster strategy aligns well with regulatory expectations for diseases with seasonal exposure patterns, increasing the likelihood of positive review.
Business Significance
Advertisement
For Valneva and partner Pfizer, VLA15 represents a major commercial opportunity in a market with no approved Lyme disease vaccines despite a rapidly growing global burden. As mentioned on page 1, Lyme disease affects approximately 476,000 people annually in the U.S. and 132,000 in Europe, highlighting the significant unmet demand for a preventive solution. Successful advancement of VLA15 strengthens Valneva’s vaccine pipeline and supports its commercial strategy, which currently includes three marketed travel vaccines. For Pfizer, the collaboration offers leadership in a new high-impact vaccine category, with VLA15 poised to become the first modern Lyme disease vaccine to reach commercialization. The strong Phase 2 data improve investor confidence and support revenue projections tied to the vaccine’s anticipated global uptake.
Patients’ Significance
Lyme disease remains the most common vector-borne illness in the Northern Hemisphere, and as described on page 2, early symptoms can be nonspecific and easily missed, leading to serious long-term complications such as arthritis, carditis, and neurological manifestations. The absence of an approved vaccine leaves individuals—particularly those living in endemic regions—without a proven preventive option. VLA15’s strong immunogenicity across all ages, including children as young as five, offers profound patient benefit by reducing infection risk before seasonal exposure. The vaccine’s ability to generate robust and persistent antibody levels also supports public health strategies aimed at decreasing Lyme-associated morbidity.
Policy Significance
As Lyme disease cases climb due to shifting tick habitats and climate-driven geographic expansion, VLA15 carries important public-health and policy relevance. Page 2 of the file emphasizes the growing medical need for vaccination amid rising incidence and widening endemic zones. A safe and effective Lyme vaccine could help reduce the substantial healthcare burden associated with late-stage complications, misdiagnoses, and repeated antibiotic treatments. Policymakers may also view VLA15 as a strategic tool for preventive disease management, especially in high-risk regions across the U.S. and Europe. Its eventual approval would likely influence vaccination guidelines, coverage decisions, and seasonal public-health planning, supporting long-term disease mitigation efforts.
Valneva’s final Phase 2 results for VLA15 reinforce its potential as a first-in-class Lyme disease vaccine, demonstrating strong antibody persistence, consistent safety, and broad multi-serotype coverage. With Phase 3 dosing complete and regulatory submissions targeted for 2026, VLA15 stands at the forefront of efforts to deliver a transformative vaccine solution to a growing global threat. These findings mark a critical step toward providing adults, adolescents, and children in endemic regions with a reliable preventive tool and highlight the substantial scientific, regulatory, and public-health progress achieved by Valneva and Pfizer in tackling one of the world’s most persistent vector-borne diseases.
Source: Valneva press release
